Aurinia Pharmaceuticals (NASDAQ:AUPH) Raised to Strong-Buy at Zacks Research

Posted by Geri Gentry on Jul 1st, 2026

Aurinia Pharmaceuticals (NASDAQ:AUPH – Get Free Report) (TSE:AUP) was upgraded by analysts at Zacks Research from a “hold” rating to a “strong-buy” rating in a report released on Monday,Zacks.com reports.

Separately, Weiss Ratings downgraded Aurinia Pharmaceuticals from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Friday, May 15th. One analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and four have assigned a Hold rating to the stock. According to MarketBeat.com, Aurinia Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average price target of $17.25.

Read Our Latest Stock Analysis on Aurinia Pharmaceuticals

Aurinia Pharmaceuticals Stock Up 1.1%

NASDAQ:AUPH opened at $16.97 on Monday. The company has a debt-to-equity ratio of 0.08, a current ratio of 5.55 and a quick ratio of 5.01. The company’s fifty day moving average price is $16.01 and its 200-day moving average price is $15.37. Aurinia Pharmaceuticals has a 1-year low of $7.28 and a 1-year high of $19.25. The firm has a market capitalization of $2.18 billion, a P/E ratio of 7.82 and a beta of 1.41.

Aurinia Pharmaceuticals (NASDAQ:AUPH – Get Free Report) (TSE:AUP) last posted its earnings results on Thursday, May 7th. The biotechnology company reported $0.25 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.18 by $0.07. Aurinia Pharmaceuticals had a net margin of 99.97% and a return on equity of 26.62%. The company had revenue of $77.71 million during the quarter, compared to the consensus estimate of $76.98 million. As a group, equities research analysts anticipate that Aurinia Pharmaceuticals will post 0.82 EPS for the current year.

Insider Buying and Selling

In other news, CEO Kevin Tang acquired 206,005 shares of the business’s stock in a transaction on Tuesday, June 2nd. The stock was bought at an average price of $15.28 per share, with a total value of $3,147,756.40. Following the completion of the acquisition, the chief executive officer owned 13,044,106 shares of the company’s stock, valued at approximately $199,313,939.68. This represents a 1.60% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through the SEC website. Insiders have acquired a total of 814,606 shares of company stock worth $12,455,129 in the last quarter. 12.20% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Aurinia Pharmaceuticals

Hedge funds have recently modified their holdings of the company. BOK Financial Private Wealth Inc. acquired a new stake in shares of Aurinia Pharmaceuticals during the 4th quarter valued at about $32,000. Frazier Financial Advisors LLC raised its holdings in Aurinia Pharmaceuticals by 411.9% in the 1st quarter. Frazier Financial Advisors LLC now owns 3,471 shares of the biotechnology company’s stock worth $51,000 after purchasing an additional 2,793 shares during the period. Northwestern Mutual Wealth Management Co. acquired a new position in Aurinia Pharmaceuticals in the 3rd quarter worth about $48,000. Kemnay Advisory Services Inc. purchased a new position in Aurinia Pharmaceuticals during the fourth quarter worth approximately $82,000. Finally, Mirae Asset Global Investments Co. Ltd. boosted its position in Aurinia Pharmaceuticals by 25.9% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 6,407 shares of the biotechnology company’s stock worth $102,000 after purchasing an additional 1,318 shares in the last quarter. 36.83% of the stock is owned by hedge funds and other institutional investors.

About Aurinia Pharmaceuticals

(Get Free Report)

Aurinia Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company focused on developing and commercializing therapies for autoimmune diseases. The company’s proprietary molecule, voclosporin, is designed to selectively inhibit calcineurin and reduce inflammation associated with autoimmune responses. Aurinia operates research and development facilities in Canada and the United States, leveraging collaborations with academic institutions and contract research organizations to advance its clinical pipeline.

The company’s lead product, voclosporin (marketed as LUPKYNIS), received approval from the U.S.